In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
US rare diseases specialist Soligenix closed 19% lower after Tuesday’s trading following news of a setback with its lead drug candidate. 15 February 2023
Biotechnology
Canadian precision meds company Fusion Pharmaceuticals has announced the acquisition from Texas, USA-based RadioMedix, of the investigational new drug application (IND) for an ongoing Phase II clinical trial. 15 February 2023
Biotechnology
Shares of US biotech Gritstone bio were up 2.23% t $2.67 pre-marker as the company, announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the USA’s National Institutes of Health. 15 February 2023
Pharmaceutical
Florida, USA-based Axogen, which is developing and marketing innovative solutions for peripheral nerve injuries, has announced the appointment of Jens Schroeder Kemp to the newly created role of chief marketing officer. 15 February 2023
Biotechnology
Chinese biotech Clover Biopharmaceuticals has launched its COVID-19 vaccine in China. 14 February 2023
Biotechnology
UK pharma major GSK is discontinuing its collaboration with Vir Biotechnology on vaccines against COVID-19, with Vir continuing to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners. 14 February 2023
Biotechnology
German life sciences and technology company Merck KGaA has announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. 14 February 2023
Pharmaceutical
The range medicines available in Russian pharmacies is steadily declining, which is mainly due to tough economic environment in the country, caused by Western sanctions and the existing problems with logistics, reports The Pharma Letter’s local correspondent. 14 February 2023
Biotechnology
Last week’s US Food and Drug Administration (FDA) clinical hold on genetic medicines company 4D Molecular Therapeutics Fabry disease (FD) gene therapy program (4D-310) could benefit fellow US drugmaker Sangamo Therapeutics. 14 February 2023
Pharmaceutical
Sorrento Therapeutics, a US company focused on acquiring, developing and commercializing non-opioid pain management products, has issued a statement alongside its majority-owned subsidiary Scilex Holding Company. 14 February 2023
Pharmaceutical
Shares of US regenerative medicines firm Frequency Therapeutics plummeted more than 80% to $0.75 yesterday, after it announced it is terminating programs in sensorineural hearing loss (SNHL) because FX-322 failed to meet the goal of a study in people with acquired SNHL, and is slashing its workforce. 14 February 2023
Pharmaceutical
Following the announcement that Sanofi’s global head of R&D John Reed is leaving the French drugmaker, his destination has been revealed as the US healthcare giant Johnson & Johnson. 14 February 2023
Biotechnology
China and USA-based Harbour BioMed saw its shares rise more than 7% to HK$3.17, after it announced an exclusive license agreement with US firm Cullinan Oncology for the development and commercial rights on HBM7008 (CLN-418) in the USA. 14 February 2023
Biosimilars
The advent of biologics has opened doors for the treatment of several acute and chronic medical conditions.1 Unlike conventional medicines, biologics are derived from living organisms using complex biomedical processes. As a result, development of biologics is more complicated as compared to conventional drugs.2 14 February 2023
Biotechnology
French drugmaker Ipsen has announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx (cabozantinib) and Opdivo (nivolumab) improve survival and response rate after three-years in the first-line treatment of advanced renal cell carcinoma, compared to sunitinib. 14 February 2023
Biotechnology
Australian biotech company CSL Limited , the world's No 2 influenza vaccine provider in sales, today released financial results for the fist half of fiscal year 2022/23, showing that total revenues were up 19% to US$7.184 billion, US$889 million of which is attributable to CSL Vifor. 14 February 2023
Pharmaceutical
Leaked proposals for the European Commission’s (EC) Pharmaceutical Review package have angered an industry group. 13 February 2023
Pharmaceutical
Shares of US ophthalmic drug developer Ocuphire Pharma were lifted 7.6% to $3.53 this morning, as the company updated on the development of its lead product candidate. 13 February 2023
Pharmaceutical
French drugmaker Sanofi is searching for a new global head of R&D after the role’s current incumbent John Reed announced he was off to pursue an undisclosed opportunity outside the company. 13 February 2023
Biotechnology
G1 Therapeutics’ shares fell 51.8% to $3.43 pre-market today, as the US oncology drug developer said it would terminate a study of its lead drug, trilaciclib, as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer. 13 February 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze